Início › Câncer de Ovário › Carolina do Norte › Durham
Ensaios clínicos de Câncer de Ovário em Durham, NC
27 estudos para Câncer de Ovário estão buscando participantes em locais em Durham e arredores (num raio de aproximadamente 30 milhas). Abra um estudo para ver quem pode participar e como contatar a equipe.
Texto oficial do estudo (Inglês)
Recrutando participantes para um estudo? Destaque-o no topo desta página — $99 por 30 dias →
The Vanguard Study: Testing a New Way to Screen for Cancer
RecrutandoVoluntários saudáveis bem-vindos
- Durham VA Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · a 10 mi de distância
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
RecrutandoFase 2/3
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · a 10 mi de distância
- University of North Carolina-Hillsborough Campus, Hillsborough · a 13 mi de distância
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
RecrutandoFase 2
- Duke University Medical Center, Durham
A Study of PHST001 in Advanced Solid Tumors
RecrutandoFase 1
- Duke Cancer Institute, Durham
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RecrutandoFase 1/2
- Duke University, Durham
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
RecrutandoFase 2
- University of North Carolina Medical Center /ID# 275307, Chapel Hill · a 10 mi de distância
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RecrutandoFase 2
- Site 0259 - Duke Cancer Center, Durham
DESTINY-PANTUMOUR04
RecrutandoEstudo observacional
- Research Site, Durham
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
RecrutandoFase 3
- Duke Cancer Institute, Durham
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
RecrutandoFase 1
- Duke University Medical Center, Durham
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
RecrutandoFase 3
- Duke Cancer Center ( Site 0012), Durham
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
RecrutandoEstudo observacional
- UNC- Chapel Hill, Chapel Hill · a 10 mi de distância
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
RecrutandoFase 3
- Duke, Durham
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Recrutando
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · a 10 mi de distância
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
RecrutandoFase 3
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · a 10 mi de distância
CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer
RecrutandoFase 1/2
- Duke University, Durham
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
RecrutandoFase 3
- UNC Hospital, Chapel Hill · a 10 mi de distância
Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells
RecrutandoFase 1
- Lineberger Comprehensive Cancer Center, Chapel Hill · a 10 mi de distância
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
RecrutandoFase 3
- Duke Cancer Center, Durham
REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors
Recrutando
- Duke Cancer Center, Durham
A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer
RecrutandoFase 1
- Site 0259, Durham
TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention
Recrutando
- Duke University Hospital, Durham
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
RecrutandoFase 1/2
- Duke Cancer Center/ DUMC, Durham
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
RecrutandoFase 1
- Duke Cancer Institute, Durham
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
RecrutandoFase 2
- Duke Cancer Center, Durham
Multimedia Aid for Genetic Testing in Gynecologic Oncology
Recrutando
- Univeristy of North Carolina at Chapel Hill, Chapel Hill · a 10 mi de distância
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecrutandoEstudo observacional
- Massive Bio SYNERGY-AI site, Chapel Hill · a 10 mi de distância
Ensaios de Câncer de Ovário em outras cidades
- Houston, TX89 estudos
- New York City, NY69 estudos
- Boston, MA61 estudos
- Los Angeles, CA50 estudos
- Nashville, TN49 estudos
- Arlington, VA46 estudos
- Philadelphia, PA44 estudos
- Columbus, OH39 estudos
- St. Louis, MO38 estudos
- Chicago, IL36 estudos
- San Antonio, TX31 estudos
- Cleveland, OH30 estudos
Outros estudos em Durham
- Câncer de Mama64 estudos
- Câncer (todos os tipos)58 estudos
- Câncer de Pulmão de Não Pequenas Células39 estudos
- Mieloma Múltiplo37 estudos
- Leucemia Mieloide Aguda33 estudos
- Câncer Metastático33 estudos
- Câncer de Próstata32 estudos
- Câncer de Pulmão32 estudos
- Câncer Colorretal28 estudos
- Leucemia Linfocítica Crônica27 estudos
- Insuficiência Cardíaca26 estudos
- Câncer de Pâncreas24 estudos
Fonte: ClinicalTrials.gov, dados obtidos em 6 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.